Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q3 2015 · 10-Q
Revenue$2.01M$2.01M+10.3% vs Q3 2014 Net Income$87.94K$87.94KN/M vs Q3 2014 EPS Diluted$0.00$0.00N/M vs Q3 2014 Gross Profit$962,994+11.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flowderived$241,866N/M Margins · derivedGross margin48.0%+0.6 pt vs Q3 2014
Operating margin4.4%+20.6 pt vs Q3 2014
Net margin4.4%+20.6 pt vs Q3 2014
ended Sep 30, 2015 · filed Nov 12, 2015 · 43 d after period end